|Day Low/High||54.40 / 56.00|
|52 Wk Low/High||33.50 / 119.92|
Celgene Corporation (NASDAQ:CELG) and Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) today announced that IDHIFA ® (enasidenib) was granted approval from the U.
Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Agios Pharmaceuticals Inc.
Celgene Corporation (NASDAQ:CELG) and Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) today announced new efficacy and safety data from the ongoing Phase 1 dose-escalation and expansion study evaluating investigational oral...
Data from IDHIFA® (Enasidenib) Phase 1 Trial in IDH2m R/R AML to be Presented
The new enasidenib data -- improved tumor response rate but shorter duration -- were made public on Wednesday night in a research abstract.
Obamacare? Trumpcare? These stocks don't care.
Here's a rundown of four technical setups that are showing solid trading potential.
Investigational New Drug (IND) Submission Expected by Year End 2017
Here's how to rake in the profits off some potential big breakouts.
Celgene Corporation (NASDAQ:CELG) and Agios Pharmaceuticals (NASDAQ:AGIO) today announced that the U.